Random forest machine learning algorithm predicts virologic outcomes among HIV infected adults in Lausanne, Switzerland using electronically monitored combined antiretroviral treatment adherence.

Journal: AIDS care
PMID:

Abstract

Machine Learning (ML) can improve the analysis of complex and interrelated factors that place adherent people at risk of viral rebound. Our aim was to build ML model to predict RNA viral rebound from medication adherence and clinical data. Patients were followed up at the Swiss interprofessional medication adherence program (IMAP). Sociodemographic and clinical variables were retrieved from the Swiss HIV Cohort Study (SHCS). Daily electronic medication adherence between 2008-2016 were analyzed retrospectively. Predictor variables included: RNA viral load (VL), CD4 count, duration of ART, and adherence. Random Forest, was used with 10 fold cross validation to predict the RNA class for each data observation. Classification accuracy metrics were calculated for each of the 10-fold cross validation holdout datasets. The values for each range from 0 to 1 (better accuracy). 383 HIV+ patients, 56% male, 52% white, median (Q1, Q3): age 43 (36, 50), duration of electronic monitoring of adherence 564 (200, 1333) days, CD4 count 406 (209, 533) cells/mm3, time since HIV diagnosis was 8.4 (4, 13.5) years, were included. Average model classification accuracy metrics (AUC and F1) for RNA VL were 0.6465 and 0.7772, respectively. In conclusion, combining adherence with other clinical predictors improve predictions of RNA.

Authors

  • Susan Kamal
    Community pharmacy, School of pharmaceutical sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.
  • John Urata
    Department of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
  • Matthias Cavassini
    Infectious Disease Service, Lausanne university hospital, University of Lausanne, Lausanne, Switzerland.
  • Honghu Liu
  • Roger Kouyos
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Olivier Bugnon
    Community pharmacy, School of pharmaceutical sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.
  • Wei Wang
    State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China.
  • Marie-Paule Schneider
    Community pharmacy, School of pharmaceutical sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.